Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aumolertinib Adjuvant Therapy in Stage I NSCLC (APPOINT)
NCT04922138Phase 2Unknown
- Start
- Jan 2022
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of almonertinib in non-small cell lung cancer (NSCLC). Status: unknown.
02
Drugs
almonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04922138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04922138.